Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 2/20 | 0.35 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.37 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.37 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.37 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL3300795 | 0.95 | CES2 (0.41) | CES2CES1KIF11ALDH1A1TSHR | |
| Potassium Ion SCHEMBL30588812 | 0.95 | CES2 (0.41) | CES2CES1KIF11ALDH1A1TSHR | |
| Water SCHEMBL5129140 | 0.87 | CA1 (0.40) | KIF11EPHX2CA1CA2CA9 | |
| SCHEMBL31190515 | 0.83 | — | — | |
| SCHEMBL5397505 | 0.82 | ALDH1A1 (0.42) | CES2CES1KIF11ALDH1A1TSHR | |
| SCHEMBL11330206 | 0.77 | ALDH1A1 (0.43) | KIF11ALDH1A1TSHREPHX2SRD5A2 | |
| SCHEMBL4440029 | 0.77 | KIF11 (0.48) | KIF11PTPN1 | |
| SCHEMBL1584194 | 0.75 | CES2 (0.44) | CES2ALDH1A1TSHRFBP1MGLL | |
| SCHEMBL1827236 | 0.74 | CES2 (0.48) | CES2CES1KIF11ALDH1A1TSHR | |
| SCHEMBL161233 | 0.73 | CA1 (0.41) | CES2CES1ALDH1A1FBP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116655915-B | Polyimide compound and preparation method and application thereof | 北京建工环境修复股份有限公司 | 2023-11-03 | — | — | CN | claimed |
| CN-116655915-A | Polyimide compound and preparation method and application thereof | 北京建工环境修复股份有限公司 | 2023-08-29 | — | — | CN | claimed |
| CN-110526847-B | Synthesis method of N-aryl sulfuryl sulfoxide imine | 成都理工大学 | 2021-01-19 | — | — | CN | claimed |
| CN-122051385-A | Additive for improving safety performance of electrolyte, electrolyte and battery | 孝感楚能新能源创新科技有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20250275952-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | MYOKARDIA INC (US) | 2025-09-04 | — | — | US | disclosed |
| CN-116082204-B | Beta-sulfinyl alkenyl sulfone compound and preparation method and application thereof | 华南师范大学 | 2024-07-12 | — | — | CN | disclosed |
| CN-117946101-A | Aryl methyl sulfone compound and synthesis method thereof | 中国人民解放军军事科学院防化研究院 | 2024-04-30 | — | — | CN | disclosed |
| CN-115197108-B | Preparation method of gamma-ketosulfone compound | 南华大学 | 2023-11-28 | — | — | CN | disclosed |
| EP-4234017-A2 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS USEFUL FOR THE TREATMENT OF CARDIAC DISORDERS SUCH AS DILATED CARDIOMYOPATHY (DCM) | MyoKardia, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3450623-B1 | METHOD FOR CONTROLLING GROWTH OF MICROORGANISMS AND/OR BIOFILMS IN AN INDUSTRIAL PROCESS | KEMIRA OYJ (FI) | 2023-06-28 | — | — | EP | disclosed |
| EP-3676445-B1 | METHOD FOR CONTROLLING GROWTH OF MICROORGANISMS AND/OR BIOFILMS IN AN INDUSTRIAL PROCESS | KEMIRA OYJ (FI) | 2023-05-31 | — | — | EP | disclosed |
| WO-2016118774-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS FOR THE TREATMENT OF DILATED CARDIOMYOPATHY (DCM) | MyoKardia, Inc. (US) | 2016-07-28 | — | — | WO | disclosed |
| US-9067949-B2 | Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-HT6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| WO-2014028669-A1 | NOVEL COMPOUNDS FOR MODULATION OF ROR-GAMMA ACTIVITY | BIOGEN IDEC MA INC. (US) | 2014-02-20 | — | — | WO | disclosed |
| EP-2668191-A2 | BENZOFURO[3,2-C]PYRIDINES AND RELATED ANALOGS AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS FOR THE TREATMENT OF OBESITY, METABOLIC SYNDROME, COGNITION AND SCHIZOPHRENIA | Albany Molecular Research, Inc. (US) | 2013-12-04 | — | — | EP | disclosed |
| US-8575186-B2 | Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| WO-2012099952-A2 | BENZOFURO[3,2-C] PYRIDINES AND RELATED ANALOGS AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS FOR THE TREATMENT OF OBESITY, METABOLIC SYNDROME, COGNITION AND SCHIZOPHRENIA | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-26 | — | — | WO | disclosed |
| US-20120184531-A1 | BENZOFURO[3,2-c] PYRIDINES AND RELATED ANALOGS AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS FOR THE TREATMENT OF OBESITY, METABOLIC SYNDROME, COGNITION AND SCHIZOPHRENIA | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20110112122-A1 | EPIMINOCYCLOALKYL[b] INDOLE DERIVATIVES AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| WO-2011044134-A1 | EPIMINOCYCLOALKYL(B)INDOLE DERIVATIVES AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112122-A1 | EPIMINOCYCLOALKYL[b] INDOLE DERIVATIVES AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS AND USES THEREOF | HTR6, HTR3B, HTR1B | CA1 4157/4885CA2 4684/4885CES2 213/4885 |
| US-20250275952-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | TNNI3, UMPS, TNNT2 | CA1 4853/4885CA2 4608/4885CES2 2809/4885 |
| US-20120184531-A1 | BENZOFURO[3,2-c] PYRIDINES AND RELATED ANALOGS AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS FOR THE TREATMENT OF OBESITY, METABOLIC SYNDROME, COGNITION AND SCHIZOPHRENIA | HTR6, HTR5A, HTR2C | CA1 4874/4885CA2 4719/4885CES2 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.